CLONIDINE REBOUND HYPERTENSION

InPharma ◽  
1976 ◽  
Vol 25 (1) ◽  
pp. 7-7
Keyword(s):  
1980 ◽  
Vol 96 (4) ◽  
pp. 762-766 ◽  
Author(s):  
S.P. Makker ◽  
B. Moorthy
Keyword(s):  

2018 ◽  
Vol 41 (4) ◽  
pp. 263-274 ◽  
Author(s):  
Kumiko Taguchi ◽  
Nanami Bessho ◽  
Mami Hasegawa ◽  
Haruka Narimatsu ◽  
Takayuki Matsumoto ◽  
...  

1976 ◽  
Vol 295 (21) ◽  
pp. 1175-1177 ◽  
Author(s):  
Hans J. Keim ◽  
Jan I. Drayer ◽  
David B. Case ◽  
Jorge Lopez-Ovejero ◽  
John M. Wallace ◽  
...  

2007 ◽  
Vol 31 (7) ◽  
pp. 274-275 ◽  
Author(s):  
Alka S. Ahuja ◽  
Rahul Srivastava
Keyword(s):  

1981 ◽  
Vol 25 (1) ◽  
pp. 16
Author(s):  
J. E. COTTRELL ◽  
P. ILLINER ◽  
M. J. KITTAY ◽  
J. M. STEELE ◽  
J. LOWENSTEIN ◽  
...  

1980 ◽  
Vol 27 (1) ◽  
pp. 32-36 ◽  
Author(s):  
James E Cottrell ◽  
Pavel Illner ◽  
Michael J Kittay ◽  
John M Steele ◽  
Jerome Lowenstein ◽  
...  

1988 ◽  
Vol 22 (7-8) ◽  
pp. 573-574 ◽  
Author(s):  
Maren Stewart ◽  
James F. Burris

Rebound hypertension with a neurological complication occurred during an attempt to substitute transdermal for oral clonidine in a patient with severe hypertension. Published studies have not established an unequivocal correlation between previous oral clonidine dose and the dose of transdermal clonidine required for equally effective antihypertensive therapy. Close observation of blood pressure may be advisable for at least one week following substitution of transdermal for oral clonidine, especially in patients with severe hypertension.


Sign in / Sign up

Export Citation Format

Share Document